The company is a main board listed company whose main business is medical services. The company currently has a number of dental and reproductive health care institutions, and is committed to becoming the leading comprehensive medical platform in China. As a benchmark enterprise in the field of dental care services in China, the company will continue to deepen the “trinity of clinical, scientific research and teaching” strategy in 2024, further consolidating its leading position in the industry. The company's main products are medical services, management services, decoration services, sales of dental materials and equipment, etc. The company won the top 50 most competitive listed companies in China Pharmaceuticals, was selected as one of the top 100 most promising listed companies in China by Forbes for five consecutive years, and is the vice chairman unit of the Zhejiang Health Industry Federation. It was included in the MSCI China A-share Onshore Index in August 2018, ranked 18th in the 2019 China Capital Annual Listed Company Value Ranking TOP100, and was awarded the 1st BMC “Excellent Private Enterprise Management Company” by Deloitte and “Harvard Business Review” and others. The “Most Growing Company Award” was selected as one of the top 200 listed SMEs in Asia by Forbes in 2019.